Regenerative Medicine Market, Global Forecast upto 2024
- April, 2018
- Domain: Healthcare - Biotechnology
- Get Free 10% Customization in this Report
Overview: Regenerative medicine is an interdisciplinary field that applies life science and engineering principles for the regeneration or repair of injured/diseased tissues or organs resulting from various causes including, disease, defects, trauma and aging. The field includes the generation and use of tissue engineering, therapeutic stem cells and the production of artificial organs. It also allows scientists to grow organs or tissues in the lab and implant them in the body safely when the body fails to heal itself. Notably, it has great potential to solve the problem of organ shortage. According to the estimation of World Health Organization, there is an increasing prevalence of diabetes among adults over the age of 18 years, that has increased to 8.5% in 2014 compared to 4.5% in 1980 across the globe. As per the estimation of Arthritis Foundation, the number of people expected to be diagnosed from arthritis will be more than 78 million, by 2040.
The market for regenerative medicine is driven by increasing prevalence of neuronal disease, cancer and genetic disease, emerging application of regenerative medicine, and advancement in technology. Huge number of ongoing clinical trails and strong product pipeline are providing market growth oppurtunity. High cost of the treatment, regulatory issues and ethical issuesare hampering the market growth.
Market Analysis: The “Global Regenerative Medicine market” is estimated to witness a CAGR of 16.6% during the forecast period 2018–2024. The global market is analyzed based on three segments – Therapy, Application and regions.
Regional Analysis: The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global regenerative medicine market, followed by Europe. Asia-Pacific region is expected to have the fastest growth rate with the market growth centered at Japan, China and India. This is mainly due to increasing funding in healthcare research, rising research activities, growing patient pool, flexible regulatory environment for clinical trials, and rising healthcare expenditure.
Therapy Analysis: Immunotherapy occupied major market share of global regenerative medicine market in 2017, and is expected to remain same during the forecasted period. Increasing product approvals, emerging technological advancements in cell and gene therapy, flexible regulatory for stem cell based research, and growing awareness regarding the benefits of stem cell therapies.
Application Analysis: The market by application is segmented into cancer, central nervous system, orthopedic and musculoskeletal, diabetes, dermatology, cardiovascular and others. Among various application, dermatology occupied the largest share in 2017 and cancer segment is expected to grow at fastest rate during the forecasted period. Growing aging population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.
Key Players: Allergan plc, Integra lifesciences, Mimedx Group, Inc., Medtronic plc, Organogenesis Inc., Zimmer Biomet, Acelity L.P. Inc., Nuvasive, Inc., Stryker Corporation, Japan Tissue Engineering Co., Ltd. (Fujifilm Holdings Corporation subsidiary), Osiris Therapeutics, Inc., Vericel Corporation and other predominate and niche players.
Competitive Analysis: Currently dermatology segment dominates the global regenerative medicine segment. A lot of researches are going on cancer, CNS, cardiovascular, orthopedic & musculoskeletal applications. The increasing importance of regenerative medicine has resulted in the launch of new products and also increased acquisition, approvals, funding to develop new product. For instance, in August 2017, Tissue Regenix Group plc completed the acquisition of acquisition of CellRight Technologies, an US based specialist in regenerative osteoinductive bone scaffolds. In April 2018, Roche acquired a program named Inception 5, focused on regenerative therapies for multiple sclerosis. In May 2018, Novartis received second FDA approval for Kymriah, CAR-T cell therapy for B-cell acute lymphoblastic leukemia (ALL).
Benefits: The report provides complete details about the usage and adoption rate of regenerative medicine in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
1 Industry Outlook
1.1 Industry Overview
1.2 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Advantages of Regenerative Medicines
3.3 Disadvantages of Regenerative Medicine
3.4 Segmented Addressable Market
3.5 Trends in the Global Regenerative Medicines Market
3.6 Related Markets
3.6.1 Wound Biologics
3.6.2 Stem Cell Banking
4 Market Outlook
4.1 Market Segmentation
4.2 PEST Analysis
4.3 Porter 5(Five) Forces
5 Market Characteristics
5.1 DRO – Market Dynamics
22.214.171.124 Increasing incidences of various diseases
126.96.36.199 Wide application range of regenerative medicines
188.8.131.52 Technological advancements
184.108.40.206 Huge number of ongoing clinical trials and strong portfolio of product pipeline
220.127.116.11 Increased collaboration and partnerships
18.104.22.168 High treatment cost
22.214.171.124 Ethical issues
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Therapy: Market Size and Analysis
6.2 Cell Therapy
6.3 Gene Therapy
6.4 Tissue Engineering
6.5 Biologics & Small Molecules
7 Applications: Market Size and Analysis
7.3 Central Nervous System (CNS)
7.5 Cardiovascular Disease
7.7 Orthopedic & Musculoskeletal Disorders
8 Regions: Market Size and Analysis
8.2 North America
8.4 Asia Pacific
8.5 Rest of the World
9 Competitive Landscape
10 Vendor Profiles
10.1 Medtronic Plc
10.1.2 Business Units
10.1.3 Geographic Revenue
10.1.4 Business Focus
10.1.5 SWOT Analysis
10.1.6 Business Strategies
10.2 Organogenesis Inc.
10.2.2 Business Focus
10.2.3 SWOT Analysis
10.2.4 Business Strategies
10.3 Integra Life Sciences Corp.
10.3.2 Business Units
10.3.3 Geographic Revenue
10.3.4 Business Focus
10.3.5 SWOT Analysis
10.3.6 Business Strategies
10.4 MiMedx Group
10.4.2 Business Focus
10.4.3 SWOT Analysis
10.4.4 Business Strategies
10.5 Zimmer Biomet Holdings Inc.
10.5.2 Business Units
10.5.3 Geographic Revenue
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategies
11 Companies to Watch for
11.1 Novartis AG
11.2 Allergan plc
11.3 Vericel Corp.
11.4 NuVasive Inc.
11.5 Vertex Pharmaceuticals Inc.
11.6 Acelity LP
11.7 Osiris Therapeutics Inc.
TABLE 1 GLOBAL REGENERATIVE MEDICINE MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 39
TABLE 2 OTHER PROMINENT VENDORS OF REGENERATIVE MEDICINE MARKET 49
TABLE 3 MEDTRONIC PLC: OFFERINGS 50
TABLE 4 MEDTRONIC PLC: RECENT DEVELOPMENTS 51
TABLE 5 ORGANOGENESIS INC: OFFERINGS 63
TABLE 6 ORGANOGENESIS INC: RECENT DEVELOPMENTS 64
TABLE 7 INTEGRA LIFE SCIENCES CORP.: OFFERINGS 66
TABLE 8 INTEGRA LIFE SCIENCES CORP.: RECENT DEVELOPMENTS 66
TABLE 9 MIMEDX: OFFERINGS 72
TABLE 10 MIMEDX GROUP: RECENT DEVELOPMENTS 73
TABLE 11 ZIMMER BIOMET: OFFERINGS 76
TABLE 12 ZIMMER BIOMET HOLDINGS, INC.: RECENT DEVELOPMENTS 78
TABLE 13 NOVARTIS AG.: SNAPSHOT 84
TABLE 14 NOVARTIS AG: RECENT DEVELOPMENTS 85
TABLE 15 ALLERGAN PLC.: SNAPSHOT 86
TABLE 16 ALLERGAN PLC: RECENT DEVELOPMENTS 87
TABLE 17 VERICEL CORPORATION: SNAPSHOT 89
TABLE 18 VERICEL CORPORATION: RECENT DEVELOPMENTS 90
TABLE 19 NUVASIVE, INC.: SNAPSHOT 91
TABLE 20 NUVASIVE, INC.: RECENT DEVELOPMENTS 92
TABLE 21 VERTEX PHARMACEUTICAL INCORPORATED: SNAPSHOT 93
TABLE 22 VERTEX PHARMACEUTICAL INCORPORATED: RECENT DEVELOPMENTS 94
TABLE 23 ACELITY LP: SNAPSHOT 95
TABLE 24 ACELITY LP: RECENT DEVELOPMENTS 96
TABLE 25 OSIRIS THERAPEUTICS, INC: OVERVIEW 96
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.